UiPath (NYSE:PATH) Given New $28.00 Price Target at BMO Capital Markets

UiPath (NYSE:PATH) had its target price boosted by BMO Capital Markets from $24.00 to $28.00 in a report published on Thursday, Benzinga reports. They currently have a market perform rating on the healthcare company’s stock.

A number of other analysts also recently issued reports on PATH. TD Cowen raised their target price on UiPath from $25.00 to $28.00 and gave the stock an outperform rating in a research note on Thursday. Canaccord Genuity Group upped their price objective on UiPath from $27.00 to $30.00 and gave the company a buy rating in a report on Friday. Evercore ISI upped their price target on UiPath from $24.00 to $27.00 and gave the company an in-line rating in a research note on Thursday. Royal Bank of Canada raised their price objective on UiPath from $19.00 to $24.00 and gave the stock a sector perform rating in a research report on Friday, December 1st. Finally, Morgan Stanley upped their target price on shares of UiPath from $17.00 to $25.00 and gave the company an equal weight rating in a research report on Thursday. Nine analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of Hold and an average target price of $27.13.

UiPath Stock Performance

Shares of PATH stock traded up $0.32 during trading hours on Thursday, reaching $23.07. The company had a trading volume of 9,842,354 shares, compared to its average volume of 10,074,664. UiPath has a 12-month low of $12.38 and a 12-month high of $27.87. The company has a market capitalization of $13.06 billion, a price-to-earnings ratio of -135.46 and a beta of 0.97. The stock has a fifty day moving average of $23.52 and a 200-day moving average of $20.70.

Insider Buying and Selling

In other news, CFO Ashim Gupta sold 125,000 shares of the stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the transaction, the chief financial officer now owns 858,148 shares in the company, valued at approximately $19,385,563.32. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Rich Wong sold 200,000 shares of UiPath stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $23.12, for a total transaction of $4,624,000.00. Following the sale, the director now owns 429,418 shares in the company, valued at $9,928,144.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Ashim Gupta sold 125,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $22.59, for a total value of $2,823,750.00. Following the transaction, the chief financial officer now owns 858,148 shares in the company, valued at approximately $19,385,563.32. The disclosure for this sale can be found here. Insiders sold 411,000 shares of company stock worth $9,418,670 over the last 90 days. 31.03% of the stock is owned by insiders.

Institutional Trading of UiPath

Several institutional investors and hedge funds have recently bought and sold shares of PATH. Royal London Asset Management Ltd. raised its holdings in shares of UiPath by 5.9% in the third quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after buying an additional 7,742 shares during the last quarter. Barclays PLC lifted its stake in shares of UiPath by 55.2% in the 2nd quarter. Barclays PLC now owns 968,036 shares of the healthcare company’s stock worth $16,039,000 after acquiring an additional 344,499 shares during the period. O Shaughnessy Asset Management LLC purchased a new stake in shares of UiPath in the third quarter valued at about $203,000. Invesco Ltd. increased its stake in shares of UiPath by 2.8% during the third quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock worth $6,830,000 after acquiring an additional 10,863 shares during the period. Finally, Symmetry Partners LLC acquired a new stake in UiPath in the fourth quarter valued at about $205,000. Hedge funds and other institutional investors own 59.04% of the company’s stock.

About UiPath

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.